2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Neoplasms
19
Endometrial Neoplasms
15
Ovarian Neoplasms
11
Carcinoma, Non-Small-Cell Lung
10
Neoplasm Metastasis
7
Squamous Cell Carcinoma of Head and Neck
6
Uterine Cervical Neoplasms
5
Head and Neck Neoplasms
5
Breast Neoplasms
5
Rectal Neoplasms
4
Pancreatic Neoplasms
4
Melanoma
4
Lung Neoplasms
4
Colonic Neoplasms
4
Fallopian Tube Neoplasms
3
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Recurrence
2
Osteosarcoma
2
Multiple Myeloma
2
Locally Advanced Rectal Cancer (LARC)
2
Carcinoma, Renal Cell
2
Carcinoma, Neuroendocrine
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Turcot syndrome
1
Interventions
Radiotherapy
10
Cisplatin
9
pembrolizumab
6
Surveys and Questionnaires
6
Methods
6
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
5
fludarabine
4
Papillomavirus Vaccines
4
Early Intervention, Educational
4
Cyclophosphamide
4
Brachytherapy
4
durvalumab
3
aldesleukin
3
Vaccines, Synthetic
3
Vaccines
3
Sentinel Lymph Node Biopsy
3
Radiosurgery
3
Radiation
3
Platinum
3
Palliative Care
3
Paclitaxel
3
Nivolumab
3
Indocyanine Green
3
Gemcitabine
3
Drug Therapy
3
Carboplatin
3
Bleomycin
3
Biopsy
3
1,2-diaminocyclohexaneplatinum II citrate
3
tremelimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vulvar Neoplasms
×
dostarlimab
×
Clear all
NCT06023862
2026-05-06
DOVE
Yonsei University
Phase 2
Recruiting
198 enrolled